NGM936 / NGM Biopharma - LARVOL DELTA

Preclinical Characterization of NGM936, a Novel Bispecific T Cell Engager Targeting ILT3 for the Treatment of Acute Myeloid Leukemia with Monocytic Differentiation (ASH 2022) - "In both whole blood cytokine release assays and in TDCC assays in which cytokine secretion was measured after target engagement, induction of TNF-α, IL-6, IFN-γ, and IL-2 by NGM936 was considerably lower than that induced by a vibecotamab biosimilar (CD123 x CD3). Finally, NGM936 induced a dose-dependent depletion of circulating tumor cells in a xenograft model in which irradiated, immunodeficient NSG mice were engrafted with human PBMCs and human ILT3+ AML cells. NGM936 thus represents a promising new treatment strategy for monocytic AML, with the potential to eliminate monocytic leukemia cells while minimizing the myelotoxicity associated with ablation of healthy bone marrow."

Preclinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD123 • CD34 • CTCs • IFNG • IL2 • IL6 • TNFA

A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma (ASH 2022) - "Our work represents the first evidence and rationale for clinical development of NGM936 surrogate antibody an ILT3-targeted immunotherapy as a viable therapeutic approach for MM cell killing. These data suggest that targeting ILT3 is an effective and safe therapeutic approach in MM."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • CASP3 • CASP7

NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting (GlobeNewswire) - "NGM Biopharmaceuticals...provided additional detail today on the poster presentation given on the Company’s first disclosed preclinical bispecific program, NGM936, at the American Society of Hematology (ASH) Annual Meeting...NGM936 induced potent cytotoxicity comparable to a CD123 x CD3 biosimilar when both expanded and naïve T cells were used as effectors. Importantly, NGM936 efficiently ablated tumor cells with a range of ILT3 expression, from ~1500 copies/cell to ~40,000 copies/cell, in those studies. In addition, as reported in the poster, NGM936 did not induce T cell-dependent cytotoxicity against CD34+ hematopoietic stem cells or non-monocytic immune cells..."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting (GlobeNewswire) - "Poster presentation to showcase NGM Bio’s in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer cells; Oral presentation from the lab of Dr. Fabiana Perna at the Indiana University School of Medicine to showcase research done in collaboration with NGM Bio demonstrating the rationale for the study of NGM936 for the treatment of patients with multiple myeloma...NGM Biopharmaceuticals, Inc...announced that an abstract related to the Company’s first disclosed preclinical bispecific program, NGM936, has been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting, which will take place December 10 – 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology